Nektar Therapeutics

NKTR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-102.5M
Depreciation & Amortization $14.9M
Depreciation
Amortization
Stock-Based Compensation $10.3M
Net Cash from Operating Activities $39.7M
Investing Activities
Capital Expenditures $16.4M
Business Acquisitions
Net Cash from Investing Activities $-149.0M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $3.5M
Net Change in Cash $-106.0M
Free Cash Flow $23.3M
← Newer Page 3 of 3 Older →